Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepotastine besilate

Drug Profile

Bepotastine besilate

Alternative Names: Bepotastine; Bepreve; Betotastine; Betotastine besilate; Talion; Talion OD Tablets; TAU-284

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ube Industries
  • Developer ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Ube Industries
  • Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Butyric acids; Chlorobenzenes; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Pruritus; Urticaria
  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 01 Nov 2018 Preregistration for Allergic rhinitis in Thailand (PO) (Mitsubishi Tanabe Pharma pipeline, February 2019)
  • 01 Nov 2018 Preregistration for Urticaria in Thailand (PO) (Mitsubishi Tanabe Pharma pipeline, February 2019)
  • 14 Aug 2015 No recent reports on development identified - Phase-II for Seasonal allergic rhinitis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top